Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,118.00
Bid: 12,120.00
Ask: 12,124.00
Change: 68.00 (0.56%)
Spread: 4.00 (0.033%)
Open: 11,966.00
High: 12,162.00
Low: 11,966.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Britain's FTSE dips after Trump win though pharma, gold miners surge

Wed, 09th Nov 2016 09:58

(ADVISORY- Follow European and UK stock markets in real time onthe Reuters Live Markets blog on Eikon, see cpurl://apps.cp./cms/?pageId=livemarkets)

* FTSE 100 down 0.1 pct

* Gold miners, pharma stocks rally

* U.S.-exposed firms also gain

By Kit Rees

LONDON, Nov 9 (Reuters) - Britain's top share index fell onWednesday after a shock win for Republican Donald Trump in theU.S. presidential election sent markets lower, though goldminers and pharma stocks soared.

Trump defeated favourite Hillary Clinton in Tuesday'selection, putting the U.S. on an uncertain path and promptinginvestors to dump risky assets such as stocks.

The blue chip FTSE 100 index fell 0.1 percent to6,837.87 points by 0932 GMT, having rallied in the previoussession on expectation of a Clinton victory. The moredomestically-focused FTSE 250 index rose 0.2 pct.

The FTSE 100 had opened 2 percent lower, but recovered offits lows. Analysts cited Trump's acceptance speech as soothinginvestor nerves.

"I think the market over-reacted slightly this morning,"John Moore, advisory investment manager at Berkeley Capital,said, adding that he wouldn't be surprised if the FTSE 100turned positive.

"I think Trump is pro-business. The thing is, lookingtowards the FTSE, there are several stocks that will benefitfrom a Trump victory, such as the pharmaceuticals sector.Hillary Clinton wanted to impose tighter regulations, whereasTrump is opposed to that."

Healthcare stocks Hikma, Shire, Astrazeneca and GlaxoSmithKline rallied, gaining between 2percent to 6.7 percent on the back of Trump's win.

Pharma stocks had been losing ground in the run-up to theelection on worries that a Clinton presidency would put pressureon drug prices.

Some companies with significant exposure to the United Statesalso rose. CRH a construction firm which had been toutedas a potential beneficiary from any increase in U.S.infrastructure spending, jumped 7 percent, as it derives 50percent of its revenues from there. U.S.-focused Ashtead also soared 7.6 percent.

Investors' flight to safety buoyed shares in precious metalsminer Fresnillo, which jumped over 9 percent, alongwith Randgold Resources, which gained more than 7percent after the price of gold surged.

Shares in banking stocks, however, came underpressure, while British grocers fell after Sainsbury reported an underwhelming set of results and dropped 3.2percent. The supermarket reported a third straight decline infirst-half profit, hurt by a fall in sales. (Reporting by Kit Rees; Editing by Toby Chopra)

More News
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
5 Jan 2024 12:00

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
3 Jan 2024 08:58

LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses

(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.

Read more
3 Jan 2024 08:04

C4X receives USD11 million from AstraZeneca following NRF2 trials

(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.